SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : analysts and calls -- ML
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (167)10/3/2005 8:55:05 PM
From: tom pope  Read Replies (1) of 238
 
Thanks, Doc, for reminding me that I hadn't checked ML today:

COLY (COLY was an ML underwriting)

Coley Pharmaceutical Group Inc (COLY, $18.20, C-2-9)
Coley Pharmaceutical - Initiate with a Neutral Primarily Based on
Valuation. Our Theoretical Fair Value is $21. Lead candidate is ProMune,
a TLR9 agonist, which showed promising phase II data in the front-line of
non-small cell lung cancer - potential peak sales of $1B. Partnered with
Pfizer which will be responsible for further development. Pfizer expects to
begin two phase III trials in NSCLC by YE2005. Pipeline: Actilon (phase Ib
for hepatitis C), a partnership w/ Sanofi-Aventis for respiratory diseases, &
VaxImmune, a vaccine adjuvant for cancer & infectious disease
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News